Journal: Oncology Letters

Article Title: Adjuvant immunotherapy plus chemotherapy and maintenance immunotherapy for pulmonary lymphoepithelioma-like carcinoma with hepatitis B virus infection, KRAS mutation and high expression of programmed death ligand 1: A case report

doi: 10.3892/ol.2026.15612

Figure Lengend Snippet: Pathology and IHC of the pulmonary lymphoepithelioma-like carcinoma. (A and B) Histological analysis. (A) heterologous cells were arranged in clusters (magnification, ×40); (B) the nuclei of heterologous cells were vacuolated and the nucleoli were clear (magnification, ×200; H&E staining); the arrows point at heterologous cells. (C-I) IHC analysis. (C) Cytoplasmic CK5/6 was positive, the arrows point at positive CK5/6 cytoplasm; (D) nuclear P40 was positive; the arrows point at positive P40 nuclear; (E) thyroid transcription factor-1 was negative; (F) Napsin A was negative; (G) nuclear EBER was positive; the arrows point at positive EBER nuclear; (H) proliferation index Ki-67 positive ~50%, the arrows point at positive Ki-67 nuclear; (I) PD-L1 detection microscopic image: Tumor proportion score=55% (magnification, ×100), the arrows point at positive PD-L1 nuclear. CK, cytokeratin; PD-L1, programmed cell death ligand 1; EBER, Epstein-Barr virus-encoded small RNA; IHC, immunohistochemistry.

Article Snippet: Hybridization in situ : EBER monoclonal antibody (cat. no. 25080502; dilution, ready-to-use; Beijing Zhongshan Jinqiao Biotechnology Co., Ltd.).

Techniques: Staining, Virus, Immunohistochemistry